NCT06222437View on ClinicalTrials.gov

Semaglutide and Polycystic Ovarian Syndrome: an Emerging Treatment Strategy

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

January 31, 2025

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions
Polycystic Ovary Syndrome
Interventions
DRUG

Semaglutide

effectiveness of semaglutide in PCOS

Trial Locations (1)

75203

Clinical Research Institute at Methodist Health System, Dallas

All Listed Sponsors
lead

Methodist Health System

OTHER